Nicotinamide Riboside Encyclopedia — Scientific Background

What Is Nicotinamide Riboside Chloride?

Nicotinamide riboside chloride (CAS 23111-00-4), also known as 3-carbamoyl-1-β-D-ribofuranosylpyridinium chloride, is a pyridinium salt with the molecular formula C₁₁H₁₅N₂O₅·Cl and a molecular weight of 290.7 g/mol. It is a naturally occurring form of vitamin B3 found in milk, fruits, vegetables, and meat, and is also produced by microorganisms in fermented beverages. NR chloride occurs as a white to light brown powder that is freely soluble in water, with solubility up to 125 mg/mL.

Regulatory Status and Pharmacopoeial Standards

Nicotinamide riboside chloride holds a well-established regulatory position:

FDA Status — Nicotinamide riboside chloride is listed in the FDA Global Substance Registration System with UNII code 8XM2XT8VWI and CAS Registry No. 23111-00-4.

EFSA Novel Food Authorization — Nicotinamide riboside chloride was assessed by EFSA in the context of a Novel Food application in 2019 and subsequently authorized as a novel food for use in food supplements at a maximum daily amount of 300 mg (Commission Implementing Regulation (EU) 2020/16).

Global Standards — NR chloride conforms to specifications including assay of 90.0–103 w/w %, water content ≤2.0%, residual solvents limits, and heavy metal limits (lead ≤0.5 ppm, arsenic ≤1 ppm, mercury ≤1 ppm, cadmium ≤1 ppm).

Physiological Functions of NAD⁺

NAD⁺ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that is essential for numerous cellular processes:

• Cellular Energy Metabolism — NAD⁺ is indispensable for ATP generation and is especially key in mitochondrial energy production

• DNA Repair — NAD⁺ is a substrate for poly(ADP-ribose) polymerases (PARPs) involved in DNA repair

• Sirtuin Activation — NAD⁺ is a required cofactor for sirtuin enzymes that regulate gene expression, stress responses, and longevity

• Metabolic Regulation — NAD⁺ enables gluconeogenesis, ketogenesis, pentose phosphate production, heme and lipid synthesis, and the elimination of oxygen radicals

• Circadian Rhythm — NAD⁺ levels oscillate with the circadian clock and influence metabolic rhythms

NAD⁺ exists in a dynamic equilibrium between its oxidized form (NAD⁺) and reduced form (NADH), and this balance determines overall cellular NAD⁺ levels.

Mechanisms of Action

NAD⁺ Salvage Pathway

NR is converted to NAD⁺ through the NAD⁺ salvage pathway. NR is first phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), which is then converted to NAD⁺ by nicotinamide mononucleotide adenylyltransferases (NMNATs). This pathway is highly efficient and is the primary mechanism by which oral NR raises systemic NAD⁺ levels.

Mitochondrial Function Enhancement

NAD⁺ is essential for mitochondrial oxidative phosphorylation and ATP production. By restoring NAD⁺ levels, NR supports mitochondrial function and cellular energy metabolism, which is particularly relevant for tissues with high energy demands such as muscle, brain, and heart.

Sirtuin-Mediated Longevity Pathways

NAD⁺ is a required cofactor for sirtuin enzymes (SIRT1–SIRT7), which regulate gene expression, DNA repair, and cellular stress responses. Sirtuin activation is associated with improved metabolic function and longevity-related pathways.

Clinical Evidence

NAD⁺ Elevation — Dose-Response Studies

Clinical trials have consistently demonstrated that oral NR supplementation safely and reliably raises blood NAD⁺ levels. A randomized, double-blind, crossover study in 12 healthy participants demonstrated that single doses of 100 mg, 300 mg, and 1,000 mg NR increased NAD⁺ AUC by 48%, 59%, and 92% respectively, measured in peripheral blood mononuclear cells (PBMCs).

An eight-week randomized trial in 140 overweight adults evaluated 100, 300, and 1,000 mg NR per day and demonstrated whole-blood NAD⁺ increases of 22%, 51%, and 142% respectively. A separate randomized, placebo-controlled trial in 133 healthy/overweight participants used 100 mg, 300 mg, or 1,000 mg NR for 8 weeks, with NAD⁺ increases of 22%, 51%, and 142% compared to baseline measured after 2 weeks.

Mild Cognitive Impairment

A randomized, placebo-controlled trial in older adults with mild cognitive impairment used dose escalation to achieve and maintain a final dose of 1 g/day over 10 weeks. The target NR dose was safely achieved, as evidenced by a 2.6-fold increase in NAD⁺ levels.

Parkinson's Disease — NR-SAFE Trial

The NR-SAFE trial, a randomized, double-blind safety trial, evaluated high-dose NR in Parkinson's disease patients. Participants were randomized to NR 1,500 mg twice daily (n=10) or placebo (n=10) for four weeks. The results supported extending the dose range of NR in phase II clinical trials to 3,000 mg per day with appropriate safety monitoring.

Metabolic Health

A randomized, placebo-controlled clinical trial in obese men used 1,000 mg NR twice daily (2,000 mg/day) for 12 weeks. While NR supplementation appeared safe, it did not improve insulin sensitivity or whole-body glucose metabolism in obese, insulin-resistant men. A separate randomized, double-blind, placebo-controlled, crossover study in 13 obese participants used 1,000 mg/day NR for 6 weeks and observed small but significant improvements in body composition, sleeping metabolic rate, and skeletal muscle acetylcarnitine concentrations.

Heart Failure

A non-randomized, open-label, non-placebo-controlled study in four stage D heart failure participants used NR dose-escalation from 250 mg twice daily to 1,000 mg twice daily. NAD⁺ levels increased by 55–161%, with improved PBMC respiration and reduced inflammatory cytokines observed.

Huntington's Disease

A randomized clinical trial (J012 NAD-HD) is evaluating NR in Huntington's disease, representing an expanding scope of clinical research for this NAD⁺ precursor.

The Bioavailability Challenge

Despite its established efficacy in raising NAD⁺ levels, native NR chloride presents formulation challenges. The compound is hygroscopic and susceptible to degradation, particularly to nicotinamide, under certain conditions. NR also undergoes first-pass metabolism in the liver and intestine, which can limit its systemic bioavailability.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. Liposomal NR formulations have been shown to achieve 73% higher plasma concentrations compared to conventional NR formulations and 58% absorption compared to only 8% for non-encapsulated forms.

Liposomal Nicotinamide Riboside

Liposomal encapsulation of NR provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the NR molecule, forming a protective shell that enhances stability, absorption, and cellular uptake. This delivery system:

• Achieves 73% higher plasma concentrations compared to conventional NR

• Achieves 58% absorption compared to 8% for non-encapsulated forms

• Delivers nearly 3× higher brain concentration than conventional NR

• Protects NR from moisture absorption and oxidative degradation

• Enhances intestinal absorption through lipid-mediated pathways

A study published in ScienceDirect demonstrated that liposome-based loading enhances the distribution of nicotinamide riboside chloride into the brain and its neuroprotective effect, with NR concentration in the liposome-loading solution determined by HPLC. Liposomal encapsulation prevents NR degradation and enhances absorption, ensuring effective delivery to cells and maximizing bioavailability.

Safety and Regulatory

Nicotinamide riboside chloride is generally well tolerated. Clinical trials have used doses ranging from 100 mg to 3,000 mg per day with appropriate safety monitoring. The FDA and EFSA have approved daily doses up to 300 mg as safe for the general adult population. NR is safe and well tolerated in clinical studies, with no serious adverse events reported.

Regulatory status varies by region:

• United States — NR chloride is regulated as a dietary supplement ingredient. The FDA has established UNII code 8XM2XT8VWII.

• European Union — NR chloride was authorized as a novel food for use in food supplements at a maximum daily amount of 300 mg under Commission Implementing Regulation (EU) 2020/16.

• Australia and New Zealand — NR chloride is permitted as a form of vitamin B3 in food for special medical purposes and in formulated supplementary sports foods.

Nicotinamide riboside chloride is widely commercialized as a dietary supplement ingredient and is available in the United States, Europe, Australia, and other regions. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

199$/KG

159$/KG